



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#91K.T.
3/13EFFECT.
w/E.O.T.
4 mos.

In re Patent Application of

ROSS et al

Atty. Ref.: 4137-3

RECEIVED

Serial No. 09/581,286

Group: 1631

MAR 11 2003

Filed: June 28, 2000

Examiner: Borin, M.L.

TECH CENTER 1600/2900

For: P. GINGIVALIS POLYPEPTIDES AND
NUCLEOTIDES

* * * * *

February 28, 2003

Assistant Commissioner for Patents
Washington, DC 20231**RESPONSE**

Sir:

In response to the Official Action mailed October 1, 2002, Applicants hereby elect Group I. In response to the sequence election requirement, SEQ ID NO:424 (corresponding to peptide PG2) is elected. These elections are made with traverse.

In the Official Gazette of November 19, 1996 in the section initialed "Examination of Patent Applications Containing Nucleotide Sequences", it was stated that the PTO will permit applications to claim up to ten (10) independent and distinct nucleotide sequences in one national application. The Notice further stated that:

"Nevertheless, to further aid the biotechnology industry in protecting its intellectual property without creating an undue burden on the Office, the Commissioner has decided *sua sponte* to partially waive the requirements of 37 C.F.R. 1.141 et seq. and permit a reasonable number of such nucleotide sequences to be claimed in a single application."

03/07/2003 SZEWDIE1 00000115 09581286

01 FC:1254

1450.00 OP

715010

The Notice further states:


"Accordingly, and in most cases, up to ten (10) independent and distinct nucleotide sequences will be examined in a single application without restriction. It has been determined that normally ten (10) sequences constitute a reasonable number for examination purposes. The PTO believes that allowing applicants to claim up to ten (10) independent and distinct nucleotide sequences in a single application will promote efficient, cost-effective examination of these types of applications. In addition to the specifically selected sequences, those sequences which are patentably indistinct from the selected sequences will also be examined...".

In light of the above policy statement, it is believed that the Applicant in the present application should be permitted to retain more than one sequence in the present application and have those sequences examined in this case. Thus, Applicant would prefer SEQ ID NOs:300 and 425 which are very similar to SEQ ID NO:424 to be examined in the present application. In addition, Applicant would like to retain proteins PG13, PG35, PG47 and PG50 together with PG2. It will be noted that these five proteins are grouped together in Table 5 on page 33, on the basis that they include a TonB III Box. Modification of the requirement in the above regards is respectfully requested.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____


Leonard C. Mitchard
Reg. No. 29,009


LCM:lfm
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

ROSS et al

Serial No. 09/581,286



Atty Dkt. 4137-3

C# M#

Group Art Unit: 1631

Examiner: Borin, M.L.

Date: February 28, 2003

Filed: June 28, 2000

Title: P. GINGIVALIS POLYPEPTIDES AND NUCLEOTIDES

Assistant Commissioner for Patents
Washington, DC 20231

Sir:


RESPONSE/AMENDMENT/LETTER

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

 Correspondence Address Indication Form Attached.**Fees are attached as calculated below:**

Total effective claims after amendment	0	minus highest number		
previously paid for	20	(at least 20) =	0 x \$ 18.00	\$ 0.00
Independent claims after amendment	0	minus highest number		
previously paid for	3	(at least 3) =	0 x \$ 84.00	\$ 0.00
If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper)				\$ 0.00
Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$410.00/2 months; \$930.00/3 months)				\$ 1450.00
Terminal disclaimer enclosed, add \$ 110.00				\$ 0.00
<input type="checkbox"/> First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$750.00)				\$ 0.00
<input type="checkbox"/> Please enter the previously unentered , filed				
<input type="checkbox"/> Submission attached				
			Subtotal	\$ 1450.00
If "small entity," then enter half (1/2) of subtotal and subtract				-\$ 0.00
<input type="checkbox"/> Applicant claims "small entity" status. <input type="checkbox"/> Statement filed herewith				
Rule 56 Information Disclosure Statement Filing Fee (\$180.00)				\$ 0.00
Assignment Recording Fee (\$40.00)				\$ 0.00
Other:				0.00
			TOTAL FEE ENCLOSED	\$ 1450.00

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor, certify that this correspondence is NIXON & VANDERHYE P.C.
 Arlington, Virginia 22201-4714 is sent via the United States Postal Service By Atty: Leonard C. Mitchard, Reg. No. 29,009
 Telephone: (703) 816-4000 in an envelope addressed to: Com-
 Facsimile: (703) 816-4100ents and Trademarks, Washington,
 LCM:lrm D.C. 20231, on Feb 28 03 Signature: 

Date of deposit:
Leonard C. Mitchard, 29009

Signature

Date of this act